Is INDV Worth Buying in 2026?

Indivior Pharmaceuticals, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-05-03

Here’s whether Indivior Pharmaceuticals, Inc. Common Stock (INDV) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); strong 1-year return of +226.1%; 3-month momentum positive (+7.6%). Concerns: RSI 78 — overbought, elevated pullback risk. Currently 5.9% off its 52-week high. Score: +4/7.

Ready to act on this? 📈 Trade on Webull

INDV is in a confirmed uptrend, trading above both its 50-day ($31.98) and 200-day ($29.30) moving averages. With an RSI of 77.7, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +226.1% compares to +27.9% for SPY (beat the market by 198.2%).

$10,000 invested 1 year ago → $32,606 today
vs. S&P 500 (SPY) — same period beat market by 198.2%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($29.30)
Above 50-day MA ($31.98)
!RSI(14) neutral zone (30–70) — currently 77.7
Positive return (+226.1%)
Within 10% of period high (−5.9%)
Period Range $37.66
$10.63 $40.02
RSI (14) 77.7
0 · OversoldOverbought · 100

Key Metrics

Price$37.66
Period Return+226.1%
Period High$40.02
Period Low$10.63
Drawdown−5.9%
MA-50$31.98
MA-200$29.30
RSI (14)77.7
Avg Volume (30d)2.2M
vs. SPYbeat by 197.0%
Return Rank#100 of 1236

Trade INDV

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers